All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2021-04-13.
From the record
TG Therapeutics, Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2021-04-13) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+209.8% a year over 5 filed years; profitable in 3 of 5.
From the record
TG Therapeutics, Inc.'s 5 filed years say what it did: revenue went from $7 million in fiscal 2021 to $616 million in fiscal 2025, up 209.8% a year; it rose in 3 of 4 years; the deepest fall was 58% from fiscal 2021 to fiscal 2022; net income was positive in 3 of 5 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 6.0% a year. 0% of cash flow returned. Insiders: 2 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, TG Therapeutics, Inc.'s diluted share count grew about 6.0% a year, and dividends and buybacks returned about 0% of its net income over 3 years (its filed statements). Its officers and directors filed 2 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 69%: 69¢ of profit per shareholder dollar. Leverage 39%: owes 39¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, TG Therapeutics, Inc. earned about 69 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 48 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 39 cents per dollar of assets, and net share issuance: its share count grew 0.7% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 8% of 315 in its family; net margin 72.6%.
From the record
TG Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $616 million in fiscal 2025 ranks in the top 17% by size; a net margin of 72.6% ranks in the top 4%; revenue growth of 504.6% a year over the last 3 filed years ranks in the top 3% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 6% of 315 in its family for leadership; chief executive since 2012.
From the record
TG Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Weiss, Michael S (CEO, as filed), filing under that title since 2012-01-09, 14.8 years (top 5% of its family); the 7 officers and directors filing in the last fifteen months have been on the record a median of 13.9 years (top 3%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 7 people in charge now (top 11%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 45% of 273 in its family for room to expand.
From the record
TG Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $79 million against debt of $246 million leaves -15.7% of its assets as net cash, bottom 9% of its family; cash from operations less capital spending is -4.1% of revenue (top 31%); a gross margin of 83.7% (top 27%); research spending of 26% of revenue (bottom 31%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 16% of 306 in its family for growth drivers.
From the record
TG Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 504.6% a year over the last three filed years against 209.8% over all 5, speeding up (top 1% of its family); the newest year grew 87.4% (top 18%); research spending grew 8.5% a year (top 41%); capital spending grew 148.1% a year (top 5%) (its annual reports). TG Therapeutics, Inc. reported 5 product lines in fiscal 2025: Product at $607 million (97%), License at $9 million (2%), Royalty at $6 million (1%), and 2 more; 3 of 5 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 35% of 233 in its family for expectations against reality.
From the record
TG Therapeutics, Inc.'s newest year against its own record: revenue of $616 million in fiscal 2025 came in 82.7% below the $3.6 billion its prior three years' pace pointed to (bottom 9% of its family); net income of $447 million against a prior three-year average of $63 million (top 2%); a net margin of 72.6% against losses larger than its revenue before (top 11%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made